These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 24321258)
21. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115 [TBL] [Abstract][Full Text] [Related]
22. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522 [TBL] [Abstract][Full Text] [Related]
23. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Heng DY; Chi KN; Murray N; Jin T; Garcia JA; Bukowski RM; Rini BI; Kollmannsberger C Cancer; 2009 Feb; 115(4):776-83. PubMed ID: 19127560 [TBL] [Abstract][Full Text] [Related]
24. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461 [TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239 [TBL] [Abstract][Full Text] [Related]
26. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067 [TBL] [Abstract][Full Text] [Related]
27. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632 [TBL] [Abstract][Full Text] [Related]
30. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520 [TBL] [Abstract][Full Text] [Related]
31. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Szmit S; Langiewicz P; Złnierek J; Nurzyński P; Zaborowska M; Filipiak KJ; Opolski G; Szczylik C Kidney Blood Press Res; 2012; 35(1):18-25. PubMed ID: 21849795 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ; Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573 [TBL] [Abstract][Full Text] [Related]
33. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265 [TBL] [Abstract][Full Text] [Related]
34. Central and Eastern European experience with sunitinib in metastatic renal cell carcinoma: a sub-analysis of the global expanded-access trial. Vrdoljak E; Géczi L; Mardiak J; Ciuleanu TE; Leyman S; Zhang K; Sajben P; Torday L Pathol Oncol Res; 2015 Jul; 21(3):775-82. PubMed ID: 25557271 [TBL] [Abstract][Full Text] [Related]
35. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274 [TBL] [Abstract][Full Text] [Related]
36. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692 [TBL] [Abstract][Full Text] [Related]
37. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995 [TBL] [Abstract][Full Text] [Related]
38. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U Oncology; 2009; 76(5):350-4. PubMed ID: 19321976 [TBL] [Abstract][Full Text] [Related]